IRI | Jotup

King Oscar USA Launches All-New Salmon Product Line

Retrieved on:

Tuesday, January 16, 2024

Olive, Human rights, Skinless, Spice, SAN, Engle, DJSI, Management, Environment, Supply chain management, SSI, Dow Jones, SeaChange, IRI, Environmental policy, Salmon, Aquaculture

SAN DIEGO, Jan. 16, 2024 /PRNewswire/ -- King Oscar, the legendary Norwegian seafood producer, is proud to announce the launch of a new line of Skinless & Boneless Atlantic Salmon in Extra Virgin Olive Oil in the US.

Key Points:

"As a premium brand, our all-new salmon lineup elevates the category beyond anything consumers have seen," said King Oscar USA president, John Engle.
"All three flavor varieties feature select cuts of Atlantic salmon, unlike traditional canned 'skin-on & bone-in' salmon or skinless & boneless flake-style canned salmon.
Expect King Oscar to deliver hand-packed cuts of Atlantic salmon, marinated in extra virgin olive oil, and with a proprietary blend of spices and natural flavors in every can."
I encourage consumers to pick up a can of King Oscar Skinless & Boneless Atlantic Salmon and enjoy the way canned salmon should be served."

Arch Biopartners Receives Health Canada Approval to Conduct Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on:

Wednesday, January 10, 2024

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points:

TORONTO, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received a No Objection Letter from Health Canada to conduct a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
The Phase II trial is an international multi-center, randomized, double-blind, placebo-controlled study of LSALT peptide.
There is no treatment available in the market today that prevents acute kidney injury of the type commonly experienced by on-pump cardiac surgery patients.

US Consumer Technology Sales Expected to Resume Growth in 2024, Reports Circana

Retrieved on:

Tuesday, January 9, 2024

Computer, Sale, The NPD Group, IRI, Television, Area studies, Virtual reality, Growth, Video game

Initial results indicate that 2023 dollar sales will end 10% below the prior year, marking the second year of revenue contraction.

Key Points:

Initial results indicate that 2023 dollar sales will end 10% below the prior year, marking the second year of revenue contraction.
“Upgrade cycles for pandemic-driven purchases will ramp up in late 2024 for key large-dollar categories like computers, creating growth opportunity.”
The computer category will account for almost half of the $1.7 billion consumer technology industry growth expected in 2024.
“New products can help to reignite demand and give consumers fresh reasons to spend on consumer technology products.
This year, innovations in computing, virtual reality and home automation will contribute to the industry’s recovery,” said Ben Arnold, executive director and consumer technology industry analyst for Circana .

Infrasense Performs a Pavement Evaluation using Ground Penetrating Radar (GPR), Falling Weight Deflectometer (FWD), and Traffic Speed Deflectometer (TSD) in New Hampshire

Retrieved on:

Wednesday, January 10, 2024

Chrono Cross, GPS, DMI, Ground-penetrating radar, Software, TSD, ASTM, IRI, FWD, GSSI, GPR, CRCP, Road

EPPING, N.H., Jan. 10, 2024 /PRNewswire-PRWeb/ -- Infrasense recently conducted pavement structure/condition evaluations of a six-mile highway section in New Hampshire. A vehicle-based Ground Penetrating Radar (GPR) survey yielded continuous pavement layer thickness data along prescribed offsets within the project section. Falling Weight Deflectometer (FWD) testing was also performed at over 120 locations along the project section, which provided the data needed to calculate layer moduli, effective structural number (SN), remaining service life and required overlay thicknesses. Traffic Speed Deflectometer (TSD) data yielded deflection bowl measurements and was accompanied by surface distress data (rutting, cracking, IRI). The results provided the client with valuable information to facilitate rehabilitation design efforts. Deliverables included tabular and graphical datasets with each point linked to precise GPS coordinates. The GPR datasets help visualize how the constructed layers of the roadway change along the length of each lane, while the FWD and TSD datasets present remaining lift, overlay thickness, structural number, and subgrade modulus along the length of each lane.

Key Points:

Infrasense recently conducted Ground Penetrating Radar (GPR) and Falling Weight Deflectometer (FWD) testing along highway NH-101.
EPPING, N.H., Jan. 10, 2024 /PRNewswire-PRWeb/ -- Infrasense recently conducted pavement structure/condition evaluations of a six-mile highway section in New Hampshire.
A vehicle-based Ground Penetrating Radar (GPR) survey yielded continuous pavement layer thickness data along prescribed offsets within the project section.
Traffic Speed Deflectometer (TSD) data yielded deflection bowl measurements and was accompanied by surface distress data (rutting, cracking, IRI).

Three Years of Escalating Sales Growth Forecast in US B2B Technology, Reports Circana

Retrieved on:

Friday, January 5, 2024

Growth, The NPD Group, AI, Communication, PC, Software, B2B, IRI

Hardware sales are expected to normalize, with 3% revenue growth in 2024, followed by high single-digit gains during each of the next two years, according to the latest Future of B2B Technology Forecast from Circana , formerly IRI and The NPD Group.

Key Points:

Hardware sales are expected to normalize, with 3% revenue growth in 2024, followed by high single-digit gains during each of the next two years, according to the latest Future of B2B Technology Forecast from Circana , formerly IRI and The NPD Group.
Year-over-year performance of software and cloud platform sales have remained positive and will lead the growth in 2024.
Combined B2B tech revenue growth is forecast to reach 7% by the end of 2024.
“The B2B technology space has finally seen the bottom of the sales losses and is primed for positive performance across all segments.”

Circana to Release New Thought Leadership at CES, Featuring Prescriptive Insights for Success in 2024

Retrieved on:

Thursday, January 4, 2024

Consumer Electronics Show, IRI, Video game, Electronics, Las Vegas Convention Center, LVCC, ASP, The NPD Group, CES

Chicago, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Circana ™, formerly IRI and The NPD Group, announces new thought leadership for the upcoming Consumer Electronics Show (CES), January 9 - 12, 2024, in its latest version of Next Week Now, a compilation of insights-rich activities, announcements and events.

Key Points:

Chicago, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Circana ™, formerly IRI and The NPD Group, announces new thought leadership for the upcoming Consumer Electronics Show (CES), January 9 - 12, 2024, in its latest version of Next Week Now, a compilation of insights-rich activities, announcements and events.
The presentation will take place Monday, Jan. 8 from 2:00 – 2:40 p.m. at Las Vegas Convention Center (LVCC) West Hall, room W232.
Monday, Jan. 8 – Eighth Annual Consumer Technology Industry Performance Awards – Circana will announce the winners of its Eighth Annual Consumer Technology Industry Performance Awards.
The report features insights from Paul Gagnon and Joe Derochowski , vice president and home industry advisor at Circana.

The Simply Good Foods Company Reports Fiscal First Quarter 2024 Financial Results and Reaffirms Full Fiscal Year 2024 Net Sales and Adjusted EBITDA Outlook

Retrieved on:

Thursday, January 4, 2024

Convenience, Marketing, Depreciation, Tax, Interest, Earnings per share, IRI, Acquisition, International, Quest, Internet, Adjustment, Advertising, Growth, Investment, Overalls, GAAP, EPS, Bookkeeping

"We are pleased with our fiscal first quarter financial results and marketplace performance that were in line with estimates," said Geoff Tanner, President and Chief Executive Officer of Simply Good Foods.

Key Points:

"We are pleased with our fiscal first quarter financial results and marketplace performance that were in line with estimates," said Geoff Tanner, President and Chief Executive Officer of Simply Good Foods.
As a result, Adjusted EBITDA is expected to increase slightly higher than the net sales growth rate.
In the first quarter of fiscal 2024, total Simply Good Foods combined measured and unmeasured channel U.S. retail takeaway increased about 8%.
Given the good start to the year, the Company reaffirms its full year fiscal 2024 outlook.

Arch Biopartners Receives Approval from the Turkish Ministry of Health to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

Retrieved on:

Wednesday, January 3, 2024

TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).

Key Points:

TORONTO, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. , (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that it has received approval in Turkey from the Ministry of Health to proceed with a Phase II trial for LSALT peptide, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).
LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
With the Ministry of Health (MoH) approval for the trial, Arch can now proceed to contract and activate clinical sites in Turkey.
Once blood flow is restored to normal (reperfusion), inflammation is triggered and injury to kidney cells is exacerbated.

WORLD INSURANCE ASSOCIATES NAMES JOE KLEIN AS EVP OF NATIONAL ACCOUNTS

Retrieved on:

Tuesday, January 2, 2024

Associate, IRI, Risk management, AIG, Education, Head, Insurance, American International Group, ARM, Growth, National accounts, Aviation, Creativity, EVP

Iselin, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- World Insurance Associates LLC (World), one of the fastest growing insurance brokerages in the U.S., announced today that industry leader Joe Klein will join World as an executive vice president of its national accounts practice.

Key Points:

Iselin, NJ, Jan. 02, 2024 (GLOBE NEWSWIRE) -- World Insurance Associates LLC (World), one of the fastest growing insurance brokerages in the U.S., announced today that industry leader Joe Klein will join World as an executive vice president of its national accounts practice.
His expertise spans a wide range of industry sectors, including education, heavy manufacturing, energy, power, retail and aviation risks.
“Given the current market, insureds require more support, creativity and expertise to secure dynamic insurance programs that meet their ever-evolving needs.
Klein will be based out of Chicago and assumed his new role at World on January 2, 2024.

Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac Surgery Associated-Acute Kidney Injury Trial for LSALT Peptide

Retrieved on:

Thursday, December 21, 2023

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.

Key Points:

LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver.
The ethics committee approval of the trial will be followed by a final regulatory review conducted by the Turkish Ministry of Health (MoH), expected to be completed by mid-January.
Once the trial is approved by the MoH, activation of clinical sites in Turkey will take place and patient enrollment can begin in February.
Quote from Richard Muruve, CEO of Arch Biopartners Inc:
“We look forward to a positive decision from the MoH, which will permit enrollment of Turkish cardiac surgery patients into the trial.